Nucala — Class II drug recall D-1876-2019
Terminated recall by Cardinal Health dba Specialty Pharmaceutical Services, reported 2019-10-02, distributed nationwide. Temperature Abuse; Product stored and shipped outside of labeled storage requirements.
| Recall number | D-1876-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Cardinal Health dba Specialty Pharmaceutical Services, La Vergne, TN, United States |
| Recall initiated | 2019-09-06 |
| Classified | 2019-09-20 |
| Reported by FDA | 2019-10-02 |
| Terminated | 2020-10-08 |
| Distributed | Nationwide (US) |
| Quantity | 38 syringes |
| Reason classes | labeling, temperature control |
| NDC | 00173-0881, 00173-0881-01, 00173-0881-61, 00173-0892, 00173-0892-01, 00173-0892-42, 00173-0892-61, 00173-0892-63, 00173-0904, 00173-0904-42 |
| Lot numbers | S25X |
| Expiration dates | 2021-03-31 |
Product
Nucala (mepolizumab) Injection, 100 mg/mL Prefilled Syringe, Single-Dose, For subcutaneous use only, Rx Only, Manufactured by GlaxoSmithKline LLC, Philadelphia, PA 19112, Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0892-42.
Reason for recall
Temperature Abuse; Product stored and shipped outside of labeled storage requirements.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1876-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.